Drugs that contain Defibrotide Sodium

1. List of Defitelio drug patents

DEFITELIO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(9 years from now)

US11085043 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(9 years from now)

Do you want to check out DEFITELIO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 30, 2023

Market Authorisation Date: 30 March, 2016

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DEFITELIO family patents

6

United States

4

Korea, Republic of

2

China

1

Italy

1

Spain

1

Russia

1

Hong Kong

1

Brazil

1

Israel

1

Canada

1

Singapore

1

India

1

Mexico

1

Japan

1

Australia

1

Denmark

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in